| __timestamp | Ligand Pharmaceuticals Incorporated | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 7461000 |
| Thursday, January 1, 2015 | 24378000 | 11960000 |
| Friday, January 1, 2016 | 26621000 | 13108000 |
| Sunday, January 1, 2017 | 28653000 | 17501000 |
| Monday, January 1, 2018 | 37734000 | 22472000 |
| Tuesday, January 1, 2019 | 41884000 | 24286000 |
| Wednesday, January 1, 2020 | 64435000 | 29689000 |
| Friday, January 1, 2021 | 57483000 | 38837000 |
| Saturday, January 1, 2022 | 70062000 | 47489000 |
| Sunday, January 1, 2023 | 52790000 | 53379000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Ligand Pharmaceuticals Incorporated and Xencor, Inc. have been navigating this financial landscape since 2014. Over the past decade, Ligand Pharmaceuticals has seen its SG&A expenses grow by approximately 133%, peaking in 2022. In contrast, Xencor, Inc. has experienced a more dramatic increase of around 615% during the same period, with a notable surge in 2023.
While Ligand's expenses have fluctuated, Xencor's consistent upward trend suggests a strategic investment in administrative capabilities. However, the 2023 data reveals a pivotal moment where Xencor's SG&A expenses slightly surpassed Ligand's, indicating a potential shift in cost management strategies. As these companies continue to evolve, their ability to optimize SG&A costs will be a key factor in their financial success.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Dr. Reddy's Laboratories Limited or Xencor, Inc.: Who Manages SG&A Costs Better?
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends